Pfizer’s Xeljanz is the fist-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States, and the first targeted oral therapy to launch for the moderate to severe UC population. Not only does Xeljanz provide a novel MOA in the UC market but, as an oral therapy, it also offers a notable delivery advantage compared with the biologics and will help fulfill an unmet need. However, the entrenchment of the TNF-ɑ inhibitors could pose a formidable barrier to uptake and the agent’s positioning in the treatment algorithm is yet to be determined. The Ulcerative Colitis Emerging Therapy series includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in late May 2018 for the treatment of UC. In addition, the series will examine physician-anticipated future trends in UC treatment and in particular Xeljanz’s uptake, as well as assess Pfizer’s promotional efforts.
- What is the awareness of, familiarity with, and perceptions related to Xeljanz among U.S. gastroenterologists?
- Among prescribers, for which patients are they prescribing Xeljanz, what are the reasons for prescribing, and how satisfied are they with Xeljanz?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Xeljanz tracking compared with other recent product launches in the autoimmune market?
Emerging Therapies: is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Geography: United States
Primary research: Survey of 75 U.S. gastroenterologists for each wave.
- Unaided and aided awareness of Xeljanz.
- Familiarity with and impressions of Xeljanz.
- Prescriber and nonprescriber profiles.
- Willingness to prescribe Xeljanz.
- Performance of Xeljanz on key attributes.
- Sales representative frequency, reach, and satisfaction.
- Benchmarking against previously launched agents.
- Ulcerative Colitis - Emerging Therapies - Xeljanz (Ulcerative Colitis) Launch Tracking Wave 1
Author(s): Ritesh Gupta, PhD
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.
He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.